|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-1
|
|
pubmed:abstractText |
Progression to the castration-resistant state is the incurable and lethal end stage of prostate cancer, and there is strong evidence that androgen receptor (AR) still plays a central role in this process. We hypothesize that knocking down AR will have a major effect on inhibiting growth of castration-resistant tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
39-47
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19118031-Androgen Receptor Antagonists,
pubmed-meshheading:19118031-Animals,
pubmed-meshheading:19118031-Castration,
pubmed-meshheading:19118031-Cell Line, Tumor,
pubmed-meshheading:19118031-Gene Targeting,
pubmed-meshheading:19118031-Humans,
pubmed-meshheading:19118031-Male,
pubmed-meshheading:19118031-Mice,
pubmed-meshheading:19118031-Prostate-Specific Antigen,
pubmed-meshheading:19118031-Prostatic Neoplasms,
pubmed-meshheading:19118031-Receptors, Androgen,
pubmed-meshheading:19118031-Transplantation, Heterologous
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
|
|
pubmed:affiliation |
Prostate Center at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
